立貝韋塔單抗（HH-003）獲得美國FDA的 “突破性藥物認定”

FDA granted Breakthrough Therapy Designation to Huahui Health's Libevitug (HH-003) for treating chronic hepatitis delta virus (HDV) infection.

在美國主流藥物數據庫可以查到：  https://www.hepb.org/research-and-programs/hepdeltaconnect/drug-watch/#:~:text=Phase%20II%20(planned%20enrollment%20starting,Huahui%20Health